CLINICAL PHARMACOLOGY & THERAPEUTICS

EDITOR
C. Michael Stein, MD

EDITOR EMERITUS
Marcus M. Reidenberg, MD

FOUNDING EDITOR
Walter Modell, MD (Deceased)

ASSOCIATE EDITORS
Arthur J. Atkinson, Jr, MD
Richard B. Kim, MD
David W. Nierenberg, MD
Grant R. Wilkinson, PhD
Raymond L. Woosley, MD, PhD

EDITORIAL BOARD
Darrell R. Abernethy, MD, PhD
Adedayo Adedoyin, PhD
Matthew M. Ames, PhD
Fred Y. Aoki, MD
Glen Apseloff, MD
Larry A. Bauer, PharmD
Leif Bertilsson, PhD
Terrence F. Blaschke, MD
R. A. Branch, MD
Eric P. Brass, MD, PhD
D. Craig Brater, MD
Alastair Breckenridge, MSc, MD
Douwe D. Breimer, PhD
Michael E. Brier, PhD
James F. Burris, MD
S. George Carruthers, MD, FRCPC
Dennis J. Chapron, RPh, MS
David M. Cocchetto, PhD
C. Lindsay DeVane, PharmD
Colin Dollery, MB, ChB, BSc
Margaret S. Dordal, MD, PhD
Akio Ebihara, MD
David J. Edwards, PharmD
Merrill J. Egorin, MD
Thomas Eissenberg, PhD
William E. Evans, PharmD
Ross D. Feldman, MD
Charles Flexner, MD
Marilynn C. Frederiksen, MD
Kathleen Giacomini, PhD
Jean Gray, MD, FRCP(C)
Linda E. Gustavson, PhD
Perry V. Halushka, MD, PhD
Thomas K. Henthorn, MD
Linda A. Hershey, MD, PhD
Peter H. Hinderling, MD
Takashi Ishizaki, MD
Patrice Jaillon, MD
William J. Jusko, PhD
Shigeru Kageyama, MD, PhD
Helen Kastrissios, PhD
Joan M. Korth-Bradley, PharmD, PhD
Juan J. L. Lertora, MD, PhD
Lionel D. Lewis, MB, BCh, MD
David T. Lowenthal, MD, PhD
Carl V. Manion, MD
Edward B. Nelson, MD
Michael C. Orme, MB, BS
Russell K. Portenoy, MD
William Z. Potter, MD, PhD
Mark J. Ratain, MD
Mary V. Relling, PharmD
Janice B. Schwartz, MD
Edward M. Sellers, MD, PhD, FRCP(C)
Steven L. Shafer, MD
Lewis B. Sheiner, MD
Alexander M. M. Shepherd, MD, PhD
Sang-Goo Shin, MD, PhD
Daniel S. Sitar, PhD
Folke Sjöqvist, MD, PhD
Donald R. Stanski, MD
Arnold B. Sterman, MD
John T. Sullivan, MB, ChB, FRACP
Robert Temple, MD
Andre Terzic, MD, PhD
Timothy S. Tracy, PhD
Elliot S. Vesell, MD
Robert E. Vestal, MD
John B. Warren, MD, FRCP
William B. White, MD
John T. Wilson, MD
Alastair J. J. Wood, MB, ChB

VOLUME 71, JANUARY–JUNE 2002
MOSBY, INC, ST LOUIS

CLINICAL PHARMACOLOGY & THERAPEUTICS

Official Publication of the
American Society for Clinical Pharmacology and Therapeutics
American Society for Pharmacology and Experimental Therapeutics

EDITORIAL COMMITTEE FOR THE JOURNAL

D. Craig Brater, MD, Indianapolis, Ind (ASCPT)
Alastair J. J. Wood, MD, Nashville, Tenn (ASCPT)
Scott A. Waldman, MD, PhD, Philadelphia, Pa (ASCPT)
Perry V. Halushka, MD, PhD, Charleston, SC (ASPET)
Darrell R. Abernethy, MD, PhD, Baltimore, Md (ASPET)
Gregory L. Kearns, PharmD, Kansas City, Mo (ASCPT)
Barbara A. Levey, MD, FACP, Los Angeles, Calif (ASCPT)
John J. Schrogie, MD, King of Prussia, Pa (ASCPT)
Richard M. Weinshilboum, MD, Rochester, Minn (ASCPT)

OFFICERS OF THE AMERICAN SOCIETY FOR CLINICAL PHARMACOLOGY AND THERAPEUTICS

President: Barbara A. Levey, MD, FACP, Los Angeles, Calif
President-Elect: Gregory L. Kearns, PharmD, Kansas City, Mo
Secretary-Treasurer: John J. Schrogie, MD, King of Prussia, Pa
Chair, Editorial Committee: D. Craig Brater, MD, Indianapolis, Ind
Executive Director: Sharon J. Swan, CAE, Alexandria, Va

MEMBERS OF THE COUNCIL OF THE AMERICAN SOCIETY FOR PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

President: Marlene L. Cohen, PhD, Indianapolis, Ind
President-Elect: Paul F. Hollenberg, PhD, Ann Arbor, Mich
Secretary-Treasurer: Nancy R. Zahniser, PhD, Denver, Colo
Chair, Board of Publications Trustees: Brian M. Cox, PhD, Bethesda, Md
Executive Officer: Christine K. Carrico, PhD, Bethesda, Md

Volume 71
Copyright © 2002 by the
American Society for Clinical Pharmacology and Therapeutics
All rights reserved
Printed in the United States of America

Author index*

A

Aarnoutse RE, Grintjes KJT, Telgt DSC, Stek M, Jr., Hugen PWH, Reiss P, Koopmans PP, Hekster YA, Burger DM. The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers. 2002;71:57-67

Abdi YA. (*see* Wennerholm et al). 2002;71:77-88

Abernethy DR, Pezzullo J, Mascelli MA, Frederick B, Kleiman NS, Freedman J. Pharmacodynamics of abciximab during angioplasty: comparison to healthy subjects. 2002;71:186-95

Abernethy DR. Reply. 2002;71:403 (Letter)

Agúndez JAG. (*see* García-Martín et al). 2002;71:196-204

Anderson PL, Brundage RC, Kakuda TN, Fletcher CV. CD4 response is correlated with peak plasma concentrations of indinavir in adults with undetectable human immunodeficiency virus ribonucleic acid. 2002;71: 280-5

Andersson K. (*see* Christensen et al). 2002;71:141-52

Aoyama N. (*see* Nakamura et al). 2002;71:297-303

Arora S. (*see* Robertson et al). 2002;71:46-56

Astrup A. (*see* van Baak et al). 2002;71:272-9

Auld PAM. (*see* Ballabh et al). 2002;71:39-45

Aylward P. (*see* Robson et al). 2002;71:433-9

Azie NE. (*see* Fleishaker et al). 2002;71:169-75

B

Bailey DG. (*see* Dresser et al). 2002;71:11-20

Ballabh P, Lo ES, Kumari J, Cooper TB, Zervoudakis I, Auld PAM, Krauss AN. Pharmacokinetics of betamethasone in twin and singleton pregnancy. 2002;71:39-45

Barbey JT. Loratadine/nefazodone interaction. 2002;71:403 (Letter)

Bauer S. (*see* Kirchheiner et al). 2002;71:286-96

Becquemont L, Chazouilleres O, Serfaty L, Poirier JM, Broly F, Jaillon P, Poupon R, Funck-Brentano C. Effect of interferon α-ribavirin bitherapy on cytochrome P450 1A2 and 2D6 and N-acetyltransferase-2 activities in patients with chronic active hepatitis C. 2002;71:488-95

Behrens C. (*see* Glaeser et al). 2002;71:131-40

Beijnen JH. (*see* Mould et al). 2002;71:334-48

Beitz J. (*see* Brinker and Beitz). 2002;71:99-102

Bellissant E. (*see* Seguin et al). 2002;71:381-8

Benet LZ, Hoener B. Changes in plasma protein binding have little clinical relevance. 2002;71:115-21 (Commentary)

Benincosa LJ. (*see* Chow et al). 2002;71:235-45

Benowitz NL. (*see* Haller et al). 2002;71:421-32

Bertilsson L. (*see* Christensen et al). 2002;71:141-52

Bertilsson L. (*see* Wennerholm et al). 2002;71:77-88

Blandizzi C, Danesi R, De Paolis B, Di Paolo A, Colucci R, Falcone A, Del Tacca M. Cholinergic toxic syndrome by the anticancer drug irinotecan: acetylcholinesterase does not play a major role. 2002;71:263-71

Bodin F. (*see* van Giersbergen et al). 2002;71:253-62

Bondesen S. (*see* Schiodt et al). 2002;71:221-5

Boulton DW. (*see* Markowitz et al). 2002;71:30-8

Bräutigam L. (*see* Tegeder et al). 2002;71:153-61

Bräutigam L. (*see* Tegeder et al). 2002;71:325-33

Bredschneider M, Klein K, Mürdter TE, Marx C, Eichelbaum M, Nüssler AK, Neuhaus P, Zanger UM, Schwab M. Genetic polymorphisms of glutathione S-transferase A1, the major glutathione S-transferase in human liver: consequences for enzyme expression and busulfan conjugation. 2002;71: 479-87

Brinker A, Beitz J. Use of a spontaneous adverse drug events database for identification of unanticipated drug benefits. 2002;71:99-102

Brockmöller J. (*see* Kirchheiner et al). 2002;71:286-96

Broly F. (*see* Becquemont et al). 2002;71:488-95

Brundage RC. (*see* Anderson et al). 2002;71:280-5

Brundage RC. (*see* Grub et al). 2002;71:122-30

Brunner HR. (*see* Maillard et al). 2002;71:68-76

Brøsen K. (*see* Jürgens et al). 2002;71:162-8

Brøsen K. (*see* Jürgens et al). 2002;71:214-20

Bulitta J. (*see* Jetter et al). 2002;71:21-29

Burger DM. (*see* Aarnoutse et al). 2002;71:57-67

Burk O. (*see* Glaeser et al). 2002;71:131-40

Burnier M. (*see* Maillard et al). 2002;71:68-76

Busch CM. (*see* Zhu et al). 2002;71:311-24

C

Cai MX. (*see* Zhu et al). 2002;71:311-24

Calles NR. (*see* Grub et al). 2002;71:122-30

Carel BJ. (*see* Fleishaker et al). 2002;71:169-75

Carrillo JA. (*see* Christensen et al). 2002;71:141-52

Centeno C. (*see* Maillard et al). 2002;71:68-76

Chazouilleres O. (*see* Becquemont et al). 2002;71:488-95

Chodjania Y, Tharaux PL, Ragueneau I, Dussaule JC, Picker JL, Funck-Brentano C, Jaillon P. Renal and vascular effects of S21402, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase, in healthy subjects with hypovolemia. 2002;71:468-78

Chow FS, Benincosa LJ, Sheth SB, Wilson D, Davis CB, Minthorn EA, Jusko WJ. Pharmacokinetic and pharmacodynamic modeling of humanized anti-factor IX antibody (SB 249417) in humans. 2002;71:235-45

Christensen E. (*see* Schiodt et al). 2002;71:221-5

Christensen HR. (*see* Jürgens et al). 2002;71:162-8

Christensen HR. (*see* Jürgens et al). 2002;71:214-20

Christensen M, Tybring G, Mihara K, Yasui-Furokori N, Carrillo JA, Ramos SI, Andersson K, Dahl ML, Bertilsson L. Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19). 2002;71:141-52

Christian J. (*see* Schachtel et al). 2002;71:375-80

Chrubasik S, Pollak S, Fiebich B. Harpagophytum extracts. 2002;71:104 (Letter)

Clozel M. (*see* van Giersbergen et al). 2002;71:253-62

Colucci R. (*see* Blandizzi et al). 2002;71:263-71

Conney AH. (*see* Zhu et al). 2002;71:311-24

Cooper TB. (*see* Ballabh et al). 2002;71:39-45

D

Dahl ML. (*see* Christensen et al). 2002;71:141-52

Dahl ML. (*see* Yasar et al). 2002;71:89-98

Dandara C. (*see* Wennerholm et al). 2002;71:77-88

Danesi R. (*see* Blandizzi et al). 2002;71:263-71

d'Athis P. (*see* Tran et al). 2002;71:359-67

Davis CB. (*see* Chow et al). 2002;71:235-45

Dawson PA. (*see* Dresser et al). 2002;71:11-20

de Hoog M, Mouton JW, Schoemaker RC, Verduin CM, van den Anker JN. Extended-interval dosing of tobramycin in neonates: implications for therapeutic drug monitoring. 2002;71:349-58

DeLora P. (*see* Grub et al). 2002;71:122-30

Del Tacca M. (*see* Blandizzi et al). 2002;71:263-71

Dent J. (*see* Glaeser et al). 2002;71:131-40

De Paolis B. (*see* Blandizzi et al). 2002;71:263-71

Deray G. (*see* Izzedine et al). 2002;71:503-7

DeSmet M. (*see* van Baak et al). 2002;71:272-9

*January, pp. 1-114; February, pp. P1-P136; March, pp. 115-210; April, pp. 211-308; May, pp. 309-410; June, pp. 411-524. Index to the ASCPT meeting abstracts is located in the February issue.

DeSmet PAGM. (*see* Visser et al). 2002;71:496-502
DeVane CL. (*see* Markowitz et al). 2002;71:30-8
Dingemanse J. (*see* van Giersbergen et al). 2002;71:253-62
Di Paolo A. (*see* Blandizzi et al). 2002;71:263-71
Dorado P. (*see* Yasar et al). 2002;71:89-98
Dorent R. (*see* Izzedine et al). 2002;71:503-7
Drescher S. (*see* Glaeser et al). 2002;71:131-40
Dresser GK, Bailey DG, Leake BF, Schwarz UI, Dawson PA, Freeman DJ, Kim RB. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral bioavailability of fexofenadine. 2002;71:11-20
Duff F. (*see* Grub et al). 2002;71:122-30
Dupont C. (*see* Tran et al). 2002;71:359-67
du Souich P, Vergés J. Reply. 2002;71:304-5 (Letter)
Dussaule JC. (*see* Chodjania et al). 2002;71:468-78

E

Eichelbaum M. (*see* Bredschneider et al). 2002;71:479-87
Eichelbaum M. (*see* Glaeser et al). 2002;71:131-40
Eichler HG. (*see* Hollenstein et al). 2002;71:368-74
Eliasson E. (*see* Yasar et al). 2002;71:89-98
Erle HR. A modern pharmaceutical company. 2002:71:103 (Letter)

F

Falcone A. (*see* Blandizzi et al). 2002;71:263-71
Fardet L. (*see* Izzedine et al). 2002;71:503-7
Fiebich B. (*see* Chrubasik et al). 2002;71:104 (Letter)
Fleishaker JC, McEnroe JD, Azie NE, Francom SF, Carel BJ. Cardiovascular effect of almotriptan in treated hypertensive patients. 2002;71:169-75
Fletcher CV. (*see* Anderson et al). 2002;71:280-5
Fletcher CV. (*see* Grub et al). 2002;71:122-30
Forslund-Bergengren C. (*see* Yasar et al). 2002;71:89-98
Frampton C. (*see* Robson et al). 2002;71:433-9
Francom SF. (*see* Fleishaker et al). 2002;71:169-75
Frederick B. (*see* Abernethy et al). 2002;71:186-95
Freedman J. (*see* Abernethy et al). 2002;71:186-95
Freeman DJ. (*see* Dresser et al). 2002;71:11-20
Fromm MF. (*see* Glaeser et al). 2002;71:131-40
Fuhr U. (*see* Jetter et al). 2002;71:21-29
Fukuzawa M. (*see* Maeda et al). 2002;71:389-97
Funakoshi S. (*see* Maeda et al). 2002;71:389-97
Funck-Brentano C. (*see* Becquemont et al). 2002;71:488-95
Funck-Brentano C. (*see* Chodjania et al). 2002;71:468-78

G

García-Gamito FJ. (*see* García-Martín et al). 2002;71:196-204
García-Martín E, Martínez C, Pizarro RM, García-Gamito FJ, Gullsten H, Raunio H, Agúndez JAG. CYP3A4 alleles in white individuals with low CYP3A4 activity. 2002;71:196-204
Geick A. (*see* Glaeser et al). 2002;71:131-40
Geisslinger G. (*see* Tegeder et al). 2002;71:153-61
Geisslinger G. (*see* Tegeder et al). 2002;71:325-33
Gibb IA. (*see* Schachtel et al). 2002;71:375-80
Glaeser H, Drescher S, ven der Kuip H, Behrens C, Geick A, Burk O, Dent J, Somogyi A, von Richter O, Griese EU, Eichelbaum M, Fromm MF. Shed human enterocytes as a tool for the study of expression and function of intestinal drug-metabolizing enzymes and transporters. 2002;71:131-40
Gottesdiener KM. (*see* van Baak et al). 2002;71:272-9
Graff J. (*see* Klinkhardt et al). 2002;71:176-85
Graggaber J. (*see* Hollenstein et al). 2002;71:368-74
Griese EU. (*see* Glaeser et al). 2002;71:131-40
Grintjes KJT. (*see* Aarnoutse et al). 2002;71:57-67
Grub S, DeLora P, Ldin E, Duff F, Fletcher CV, Brundage RC, Kline MW, Calles NR, Schwarzwald H, Jorga K. Pharmacokinetics and pharmacodynamics of saquinavir in pediatric patients with human immunodeficiency virus infection. 2002;71:122-30
Grundmann-Kollmann M. (*see* Tegeder et al). 2002;71:153-61
GUARDIAN trial investigators. (*see* Weber et al). 2002;71:457-67
Gullsten H. (*see* García-Martín et al). 2002;71:196-204
Gustafsson LL. (*see* Wennerholm et al). 2002;71:77-88

H

Haller CA, Jacob P III, Benowitz NL. Pharmacology of ephedra alkaloids and caffeine after single-dose dietary supplement use. 2002;71:421-32
Hall SD. (*see* Wang et al). 2002;71:414-20
Hamman MA. (*see* Wang et al). 2002;71:414-20
Handler S. (*see* Hollenstein et al). 2002;71:368-74
Harder S. (*see* Klinkhardt et al). 2002;71:176-85
Harnisch L. (*see* Weber et al). 2002;71:457-67
Hasler J. (*see* Wennerholm et al). 2002;71:77-88
Hassan F. Reply. 2002:71:103-4 (Letter)
Hayashi H. (*see* Watanabe et al). 2002;71:398-402
Hekster YA. (*see* Aarnoutse et al). 2002;71:57-67
Hellriegel ET. (*see* Robertson et al). 2002;71:46-56
Hering M. (*see* Jetter et al). 2002;71:21-29
Hoener B. (*see* Benet and Hoener). 2002;71:115-21 (Commentary)
Hofman A. (*see* Visser et al). 2002;71:496-502
Holford NHG. (*see* Mould et al). 2002;71:334-48
Holford NHG (*see* Sheiner and Holford). 2002;71:304 (Letter)
Hollenstein U, Homoncik M, Knöbl P, Pernerstorfer T, Graggaber J, Eichler HG, Handler S, Jilma B. Acenocoumarol decreases tissue factor-dependent coagulation during systemic inflammation in humans. 2002;71:368-74
Homan HD. (*see* Schachtel et al). 2002;71:375-80
Homoncik M. (*see* Hollenstein et al). 2002;71:368-74
Honig PK. (*see* Rosebraugh et al). 2002;71:4-10 (Commentary)
Horinouchi M. (*see* Nakamura et al). 2002;71:297-303
Huang SM. (*see* Wang et al). 2002;71:414-20
Hugen PWH. (*see* Aarnoutse et al). 2002;71:57-67
Hul GBJ. (*see* van Baak et al). 2002;71:272-9
Hussain MM. (*see* Zhu et al). 2002;71:311-24
Hutson PR. (*see* Mould et al). 2002;71:334-48

I

Ingelman-Sundberg M. (*see* Wennerholm et al). 2002;71:77-88
Izzedine H, Fardet L, Launay-Vacher V, Dorent R, Petitclerc T, Deray G. Angiotensin-converting enzyme inhibitor-induced syndrome of inappropriate secretion of antidiuretic hormone: case report and review of the literature. 2002;71:503-7

J

Jacob P III. (*see* Haller et al). 2002;71:421-32
Jaillon P. (*see* Becquemont et al). 2002;71:488-95
Jaillon P. (*see* Chodjania et al). 2002;71:468-78
Jessel A. (*see* Weber et al). 2002;71:457-67
Jetter A, Kinzig-Schippers M, Walchner-Bonjean M, Hering M, Bulitta J, Schreiner P, Sörgel F, Fuhr U. Effects of grapefruit juice on the pharmacokinetics of sildenafil. 2002;71:21-9
Jilma B. (*see* Hollenstein et al). 2002:71:368-74
Jorga K. (*see* Grub et al). 2002:71:122-30
Jürgens G, Christensen HR, Brøsen K, Sonne J, Loft S, Olsen NV. Acute hypoxia and cytochrome P450-mediated hepatic drug metabolism in humans. 2002;71:214-20
Jürgens G, Lange KHW, Reuther LØ, Rasmussen BB, Brøsen K, Christensen HR. Effect of growth hormone on hepatic cytochrome P450 activity in healthy elderly men. 2002;71:162-8
Jusko WJ. (*see* Chow et al). 2002;71:235-45
Juurlink DN. Combining activated charcoal with whole-bowel irrigation. 2002; 71:404 (Letter)

K

Kakuda TN. (*see* Anderson et al). 2002;71:280-5
Kang WK. (*see* Woo et al). 2002;71:246-52
Kasbergen AAH. (*see* Visser et al). 2002;71:496-502

Kasuga M. (*see* Nakamura et al). 2002;71:297-303
Kaszkin M. Reply. 2002;71:104-5 (Letter)
Kaufmann R. (*see* Tegeder et al). 2002;71:153-61
Kim RB. (*see* Dresser et al). 2002;71:11-20
Kinzig-Schippers M. (*see* Jetter et al). 2002;71:21-29
Kirchheiner J, Brockmöller J, Meineke I, Bauer S, Rohde W, Meisel C, Roots I. Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers. 2002;71:286-96
Kirschbaum A. (*see* Tegeder et al). 2002;71:325-33
Kivistö KT. (*see* Lapatto-Reiniluoto et al). 2002;71:404-5 (Letter)
Kleiman NS. (*see* Abernethy et al). 2002;71:186-95
Klein K. (*see* Bredschneider et al). 2002;71:479-87
Kline MW. (*see* Grub et al). 2002;71:122-30
Klinkhardt U, Graff J, Harder S. Clopidogrel, but not abciximab, reduces platelet leukocyte conjugates and P-selectin expression in a human ex vivo in vitro model. 2002;71:176-85
Knöbl P. (*see* Hollenstein et al). 2002;71:368-74
Koopmans PP. (*see* Aarnoutse et al). 2002;71:57-67
Krauss AN. (*see* Ballabh et al). 2002;71:39-45
Kugaya Y. (*see* Maeda et al). 2002;71:389-97
Kuji N. (*see* Wada et al). 2002;71:440-7
Kumari J. (*see* Ballabh et al). 2002;71:39-45
Kwon K. (*see* Woo et al). 2002;71:246-52

L

Lai YL. (*see* Zhu et al). 2002;71:311-24
Lambert GH. (*see* Zhu et al). 2002;71:311-24
Lange KHW. (*see* Jürgens et al). 2002;71:162-8
Lapatto-Reiniluoto O, Kivistö KT, Neuvonen PT. Reply. 2002;71:404-5 (Letter)
Launay-Vacher V. (*see* Izzedine et al). 2002;71:503-7
Laviolle B. (*see* Seguin et al). 2002;71:381-8
Leake BF. (*see* Dresser et al). 2002;71:11-20
Le Pogamp P. (*see* Romero et al). 2002;71:226-34
Lesko LJ. (*see* Wang et al). 2002;71:414-20
Lessard Y. (*see* Seguin et al). 2002;71:381-8
Le Tulzo Y. (*see* Seguin et al). 2002;71:381-8
Liston HL. (*see* Markowitz et al). 2002;71:30-8
LLerena A. (*see* Yasar et al). 2002;71:89-98
Lo ES. (*see* Ballabh et al). 2002;71:39-45
Loft S. (*see* Jürgens et al). 2002;71:214-20
Lötsch J. (*see* Tegeder et al). 2002;71:325-33
Lüdin E. (*see* Grub et al). 2002;71:122-30

M

Maeda Y, Funakoshi S, Nakamura M, Fukuzawa M, Kugaya Y, Yamasaki M, Tsukiai S, Murakami T, Takano M. Possible mechanism for pharmacokinetic interactions between lidocaine and mexiletine. 2002;71:389-97
Maillard MP, Würzner G, Nussberger J, Centeno C, Burnier M, Brunner HR. Comparative angiotensin II receptor blockade in healthy volunteers: the importance of dosing. 2002;71:68-76
Mallédant Y. (*see* Seguin et al). 2002;71:381-8
Markowitz JS, DeVane CL, Liston HL, Boulton DW, Risch SC. The effects of probenecid on the disposition of risperidone and olanzapine in healthy volunteers. 2002;71:30-8
Martínez C. (*see* García-Martín et al). 2002;71:196-204
Marx C. (*see* Bredschneider et al). 2002;71:479-87
Mascelli MA. (*see* Abernethy et al). 2002;71:186-95
Masumori-Maemoto S. (*see* Wada et al). 2002;71:440-7
Matsuo M. (*see* Nakamura et al). 2002;71:297-303
McEnroe JD. (*see* Fleishaker et al). 2002;71:169-75
Meier S. (*see* Tegeder et al). 2002;71:153-61
Meineke I. (*see* Kirchheiner et al). 2002;71:286-96
Meisel C. (*see* Kirchheiner et al). 2002;71:286-96
Mihara K. (*see* Christensen et al). 2002;71:141-52
Minthorn EA. (*see* Chow et al). 2002;71:235-45
Mould DR, Holford NHG, Schellens JHM, Beijnen JH, Hutson PR, Rosing H, ten Bokkel Huinink WW, Rowinsky EK, Schiller JH, Russo M, Ross G. Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors. 2002;71:334-48
Mouton JW. (*see* de Hoog et al). 2002;71:349-58
Murakami T. (*see* Maeda et al). 2002;71:389-97
Mürdter TE. (*see* Bredschneider et al). 2002;71:479-87

N

Nakamura M. (*see* Maeda et al). 2002;71:389-97
Nakamura T, Sakaeda T, Horinouchi M, Tamura T, Aoyama N, Shirakawa T, Matsuo M, Kasuga M, Okumura K. Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. 2002;71:297-303
Nelson M. (*see* Robertson et al). 2002;71:46-56
Neuhaus P. (*see* Bredschneider et al). 2002;71:479-87
Neuvonen PT. (*see* Lapatto-Reiniluoto et al). 2002;71:404-5 (Letter)
Nilsson LG. (*see* Romero et al). 2002;71:226-34
Nussberger J. (*see* Maillard et al). 2002;71:68-76
Nüssler AK. (*see* Bredschneider et al). 2002;71:479-87

O

Ohashi H. (*see* Watanabe et al). 2002;71:398-402
Ohashi K. (*see* Watanabe et al). 2002;71:398-402
Okumura K. (*see* Nakamura et al). 2002;71:297-303
Olsen NV. (*see* Jürgens et al). 2002;71:214-20
Ott P. (*see* Schiødt et al). 2002;71:221-5

P

Pariente-Khayat A. (*see* Tran et al). 2002;71:359-67
Paul S. Prioritization of medical problems to improve adherence. 2002;71:211-3 (Commentary)
Penning-van Beest JA. (*see* Visser et al). 2002;71:496-502
Pernerstorfer T. (*see* Hollenstein et al). 2002;71:368-74
Petitclerc T. (*see* Izzedine et al). 2002;71:503-7
Pezzullo JC. (*see* Rosebraugh et al). 2002;71:4-10 (Commentary)
Pezzullo J. (*see* Abernethy et al). 2002;71:186-95
Picker JL. (*see* Chodjania et al). 2002;71:468-78
Pizarro RM. (*see* García-Martín et al). 2002;71:196-204
Podda M. (*see* Tegeder et al). 2002;71:153-61
Poirier JM. (*see* Becquemont et al). 2002;71:488-95
Pollak S. (*see* Chrubasik et al). 2002;71:104 (Letter)
Pons G. (*see* Tran et al). 2002;71:359-67
Poupon R. (*see* Becquemont et al). 2002;71:488-95

R

Ragueneau I. (*see* Chodjania et al). 2002;71:468-78
Ramos SI. (*see* Christensen et al). 2002;71:141-52
Ranzini AC. (*see* Zhu et al). 2002;71:311-24
Rasmussen BB. (*see* Jürgens et al). 2002;71:162-8
Raunio H. (*see* García-Martín et al). 2002;71:196-204
Reidenberg JW. (*see* Reidenberg and Reidenberg). 2002;71:309-10 (Commentary)
Reidenberg MM, Reidenberg JW. Who should have access to the research data? 2002;71:309-10 (Commentary)
Reidenberg MM. Thoughts from the Editor. 2002;71:1-2 (Commentary)
Reiss P. (*see* Aarnoutse et al). 2002;71:57-67
Reuther LØ. (*see* Jürgens et al). 2002;71:162-8
Rey E. (*see* Tran et al). 2002;71:359-67
Risch SC. (*see* Markowitz et al). 2002;71:30-8
Robertson P, Hellriegel ET, Arora S, Nelson M. Effect of modafinil on the pharmacokinetics of ethinyl estradiol and triazolam in healthy volunteers. 2002;71:46-56
Robson R, White H, Aylward P, Frampton C. Bivalirudin pharmacokinetics and pharmacodynamics: effect of renal function, dose and gender. 2002;71:433-9
Rohde W. (*see* Kirchheiner et al). 2002;71:286-96

Romero AJ, Le Pogamp P, Nilsson LG, Wood N. Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients. 2002;71:226-34
Rongen GA. (*see* van Ginnekin et al). 2002;71:448-56
Roots I. (*see* Kirchheiner et al). 2002;71:286-96
Rosebraugh CJ, Honig PK, Yasuda SU, Pezzullo JC, Woosley RL. Centers for Education and Research on Therapeutics report: survey of medication errors education during undergraduate and graduate medical education in the United States. 2002;71:4-10 (Commentary)
Rosing H. (*see* Mould et al). 2002;71:334-48
Ross G. (*see* Mould et al). 2002;71:334-48
Rowinsky EK. (*see* Mould et al). 2002;71:334-48
Russel FGM. (*see* van Ginnekin et al). 2002;71:448-56
Russo M. (*see* Mould et al). 2002;71:334-48

S

Sakaeda T. (*see* Nakamura et al). 2002;71:297-303
Sallerin V. (*see* Tran et al). 2002;71:359-67
Saris WHM. (*see* van Baak et al). 2002;71:272-9
Satoh H. (*see* Watanabe et al). 2002;71:398-402
Sayi J. (*see* Wennerholm et al). 2002;71:77-88
Schachtel BP, Homan HD, Gibb IA, Christian J. Demonstration of dose response of flurbiprofen lozenges with the sore throat pain model. 2002;71:375-80
Schellens JHM. (*see* Mould et al). 2002;71:334-48
Schiller JH. (*see* Mould et al). 2002;71:334-48
Schiødt FV, Ott P, Christensen E, Bondesen S. The value of plasma acetaminophen half-life in antidote-treated acetaminophen overdosage. 2002;71:221-5
Schmidtko A. (*see* Tegeder et al). 2002;71:325-33
Schoemaker RC. (*see* de Hoog et al). 2002;71:349-58
Schreiner P. (*see* Jetter et al). 2002;71:21-29
Schwab M. (*see* Bredschneider et al). 2002;71:479-87
Schwarz UI. (*see* Dresser et al). 2002;71:11-20
Schwarzwald H. (*see* Grub et al). 2002;71:122-30
Seguin P, Bellissant E, Le Tulzo Y, Laviolle B, Lessard Y, Thomas R, Mallédant Y. Effects of epinephrine compared with the combination of dobutamine and norepinephrine on gastric perfusion in septic shock. 2002;71:381-8
Serfaty L. (*see* Becquemont et al). 2002;71:488-95
Sheiner LB, Holford NHG. Determination of maximum effect. 2002;71:304 (Letter)
Sheth SB. (*see* Chow et al). 2002;71:235-45
Shirakawa T. (*see* Nakamura et al). 2002;71:297-303
Sjöqvist F. (*see* Yasar et al). 2002;71:89-98
Smits P. (*see* van Ginnekin et al). 2002;71:448-56
Somogyi A. (*see* Glaeser et al). 2002;71:131-40
Sonne J. (*see* Jürgens et al). 2002;71:214-20
Sörgel F. (*see* Jetter et al). 2002;71:21-29
Spink DC. (*see* Zhu et al). 2002;71:311-24
Stein M. Are herbal products dietary supplements or drugs? An important question for public safety. 2002;71:411-3 (Commentary)
Stek M, Jr. (*see* Aarnoutse et al). 2002;71:57-67
Stricker BHC. (*see* Visser et al). 2002;71:496-502
Sugimoto K. (*see* Wada et al). 2002;71:440-7
Sun LZ, Ji ZL, Chen X, Wang JF, Chen YZ. Absorption, distribution, metabolism, and excretion-associated protein database. 2002;71:405 (Letter)
Svensson JO. (*see* Wennerholm et al). 2002;71:77-88

T

Takano M. (*see* Maeda et al). 2002;71:389-97
Takeuchi K. (*see* Watanabe et al). 2002;71:398-402
Tamura T. (*see* Nakamura et al). 2002;71:297-303
Tegeder I, Bräutigam L, Podda M, Meier S, Kaufmann R, Geisslinger G, Grundmann-Kollmann M. Time course of 8-methoxypsoralen concentrations in skin and plasma after topical (bath and cream) and oral administration of 8-methoxypsoralen. 2002;71:153-61
Tegeder I, Schmidtko A, Bräutigam L, Kirschbaum A, Geisslinger G, Lötsch J. Tissue distribution of imipenem in critically ill patients. 2002;71:325-33
Telgt DSC. (*see* Aarnoutse et al). 2002;71:57-67
ten Bokkel Huinink WW. (*see* Mould et al). 2002;71:334-48
Terada H. (*see* Watanabe et al). 2002;71:398-402
Tharaux PL. (*see* Chodjania et al). 2002;71:468-78
Thomas PE. (*see* Zhu et al). 2002;71:311-24
Thomas R. (*see* Seguin et al). 2002;71:381-8
Toubro S. (*see* van Baak et al). 2002;71:272-9
Tran A, Rey E, Pons G, Pariente-Khayat A, d'Athis P, Sallerin V, Dupont C. Pharmacokinetic-pharmacodynamic study of oral lansoprazole in children. 2002;71:359-67
Tran QK. (*see* Watanabe et al). 2002;71:398-402
Treiber A. (*see* van Giersbergen et al). 2002;71:253-62
Tsukiai S. (*see* Maeda et al). 2002;71:389-97
Tybring G. (*see* Christensen et al). 2002;71:141-52
Tybring G. (*see* Yasar et al). 2002;71:89-98

U

Ueda S. (*see* Wada et al). 2002;71:440-7
Uemura S. (*see* Wada et al). 2002;71:440-7

V

van Baak MA, Hul GBJ, Toubro S, Astrup A, Gottesdiener KM, DeSmet M, Saris WHM. Acute effect of L-796568, a novel β3-adrenergic receptor agonist, on energy expenditure in obese men. 2002;71:272-9
van den Anker JN. (*see* de Hoog et al). 2002;71:349-58
van Giersbergen PLM, Treiber A, Clozel M, Bodin F, Dingemanse J. In vivo and in vitro studies exploring the pharmacokinetic interaction between bosentan, a dual endothelin receptor antagonist, and glyburide. 2002;71:253-62
van Ginneken EEM, Rongen GA, Russel FGM, Smits P. Diadenosine pentaphosphate vasodilates the forearm vascular bed: inhibition by theophylline and augmentation by dipyridamole. 2002;71:448-56
ven der Kuip H. (*see* Glaeser et al). 2002;71:131-40
Verduin CM. (*see* de Hoog et al). 2002;71:349-58
Vergés J. (*see* du Souich and Vergés). 2002;71:304-5 (Letter)
Visser LE, Penning-van Beest JA, Kasbergen AAH, DeSmet PAGM, Vulto AG, Hofman A, Stricker BHC. Overanticoagulation associated with combined use of antifungal agents and coumarin anticoagulants. 2002;71:496-502
von Richter O. (*see* Glaeser et al). 2002;71:131-40
Vulto AG. (*see* Visser et al). 2002;71:496-502

W

Wada A, Ueda S, Masumori-Maemoto S, Kuji N, Sugimoto K, Uemura S. Angiotensin II attenuates the vasodilating effect of a nitric oxide donor, glyceryl trinitrate: roles of superoxide and angiotensin II type 1 receptors. 2002;71:440-7
Walchner-Bonjean M. (*see* Jetter et al). 2002;71:21-9
Wang Z, Hamman MA, Huang SM, Lesko LJ, Hall SD. Effect of St. John's wort on the pharmacokinetics of fexofenadine. 2002;71:414-20
Watanabe H, Ohashi K, Takeuchi K, Yamashita K, Yokoyama T, Tran QK, Satoh H, Terada H, Ohashi H, Hayashi H. Sildenafil for primary and secondary pulmonary hypertension. 2002;71:398-402
Weber W, Harnisch L, Jessel A, GUARDIAN trial investigators. Lessons learned from a phase III population pharmacokinetic study of cariporide in coronary artery bypass graft surgery. 2002;71:457-67
Wennerholm A, Dandara C, Sayi J, Svensson JO, Abdi YA, Ingelman-Sundberg M, Bertilsson L, Hasler J, Gustafsson LL. The African-specific CYP2D6*17 allele encodes an enzyme with changed substrate specificity. 2002;71:77-88
White H. (*see* Robson et al). 2002;71:433-9
Wilson D. (*see* Chow et al). 2002;71:235-45
Wood N. (*see* Romero et al). 2002;71:226-34
Woo SK, Kang WK, Kwon K. Pharmacokinetic and pharmacodynamic modeling of the antiplatelet and cardiovascular effects of cilostazol in healthy humans. 2002;71:246-52

Woosley RL. (*see* Rosebraugh et al). 2002;71:4-10 (Commentary)
Würzner G. (*see* Maillard et al). 2002;71:68-76

Y

Yamasaki M. (*see* Maeda et al). 2002;71:389-97
Yamashita K. (*see* Watanabe et al). 2002;71:398-402
Yasar Ü, Forslund-Bergengren C, Tybring G, Dorado P, LLerena A, Sjöqvist F, Eliasson E, Dahl ML. Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype. 2002;71:89-98
Yasuda SU. (*see* Rosebraugh et al). 2002;71:4-10 (Commentary)
Yasui-Furokori N. (*see* Christensen et al). 2002;71:141-52
Yokoyama T. (*see* Watanabe et al). 2002;71:398-402

Z

Zanger UM. (*see* Bredschneider et al). 2002;71:479-87
Zervoudakis I. (*see* Ballabh et al). 2002;71:39-45
Zhu BT, Cai MX, Spink DC, Hussain MM, Busch CM, Ranzini AC, Lai YL, Lambert GH, Thomas PE, Conney AH. Stimulatory effect of cigarette smoking in the 15α-hydroxylation of estradiol by human term placenta. 2002;71:311-24

Subject index*

A

Abciximab
Clopidogrel, but not abciximab, reduces platelet leukocyte conjugates and P-selectin expression in a human ex vivo in vitro model (Klinkhardt et al). 2002;71:176-85
Pharmacodynamics of abciximab during angioplasty: comparison to healthy subjects (Abernethy et al). 2002;71:186-95

Acenocoumarol
Acenocoumarol decreases tissue factor-dependent coagulation during systemic inflammation in humans (Hollenstein et al). 2002;71:368-74

Acetaminophen
The value of plasma acetaminophen half-life in antidote-treated acetaminophen overdosage (Schiødt et al). 2002;71:221-5

Acetylcholinesterase
Cholinergic toxic syndrome by the anticancer drug irinotecan: acetylcholinesterase does not play a major role (Blandizzi et al). 2002;71:263-71

Acetyltransferases
Effect of interferon α-ribavirin bitherapy on cytochrome P450 1A2 and 2D6 and N-acetyltransferase-2 activities in patients with chronic active hepatitis C (Becquemont et al). 2002;71:488-95

ADME-AP database
Absorption, distribution, metabolism, and excretion-associated protein database (Sun et al). 2002;71:405 (Letter)

Adrenergic agonists
Acute effect of L-796568, a novel β3-adrenergic receptor agonist, on energy expenditure in obese men (van Baak et al). 2002;71:272-9

Adverse drug reactions
Use of a spontaneous adverse drug events database for identification of unanticipated drug benefits (Brinker and Beitz). 2002;71:99-102

Aged
Effect of growth hormone on hepatic cytochrome P450 activity in healthy elderly men (Jürgens et al). 2002;71:162-8

Alleles
The African-specific CYP2D6*17 allele encodes an enzyme with changed substrate specificity (Wennerholm et al). 2002;71:77-88
CYP3A4 alleles in white individuals with low CYP3A4 activity (García-Martín et al). 2002;71:196-204

Almotriptan
Cardiovascular effect of almotriptan in treated hypertensive patients (Fleishaker et al). 2002;71:169-75

Altitude
Acute hypoxia and cytochrome P450-mediated hepatic drug metabolism in humans (Jürgens et al). 2002;71:214-20

Analgesics
Demonstration of dose response of flurbiprofen lozenges with the sore throat pain model (Schachtel et al). 2002;71:375-80

Angioplasty
Pharmacodynamics of abciximab during angioplasty: comparison to healthy subjects (Abernethy et al). 2002;71:186-95

Angiotensin II
Angiotensin II attenuates the vasodilating effect of a nitric oxide donor, glyceryl trinitrate: roles of superoxide and angiotensin II type 1 receptors. 2002;71:440-7

Anoxia
Acute hypoxia and cytochrome P450-mediated hepatic drug metabolism in humans (Jürgens et al). 2002;71:214-20

Antibiotics
Tissue distribution of imipenem in critically ill patients (Tegeder et al). 2002;71:325-33

Antibodies, monoclonal
Gemtuzumab ozogamicin (USAN List No. 449). 2002. 71:508

Anticoagulants
Pharmacokinetic and pharmacodynamic modeling of humanized anti-factor IX antibody (SB 249417) in humans (Chow et al). 2002;71:235-45

Anticonvulsants
Levetiracetam (USAN List No. 445). 2002;71;106

Antifungal agents
Overanticoagulation associated with combined use of antifungal agents and coumarin anticoagulants (Visser et al). 2002;71:496-502

Antineoplastic agents
Cholinergic toxic syndrome by the anticancer drug irinotecan: acetylcholinesterase does not play a major role (Blandizzi et al). 2002;71:263-71
Gemtuzumab ozogamicin (USAN List No. 449). 2002;71:508
Prazarelix acetate (USAN List No. 446). 2002;71:205
Ranpirnase (USAN List No. 446). 2002;71:205

Antiparasitic agents
Selamectin (USAN List No. 447). 2002;71;307

B

Betamethasone
Pharmacokinetics of betamethasone in twin and singleton pregnancy (Ballabh et al). 2002;71:39-45

Biomarkers
Effect of growth hormone on hepatic cytochrome P450 activity in healthy elderly men (Jürgens et al). 2002;71:162-8

Bivalirudin
Bivalirudin pharmacokinetics and pharmacodynamics: effect of renal function, dose and gender (Robson et al). 2002;71:433-9

Blacks; see Ethnic groups

Blood coagulation factors
Acenocoumarol decreases tissue factor-dependent coagulation during systemic inflammation in humans (Hollenstein et al). 2002;71:368-74
Pharmacokinetic and pharmacodynamic modeling of humanized anti-factor IX antibody (SB 249417) in humans (Chow et al). 2002;71:235-45

Blood pressure
Cardiovascular effect of almotriptan in treated hypertensive patients (Fleishaker et al). 2002;71:169-75

Blood proteins
Changes in plasma protein binding have little clinical relevance (Benet and Hoener). 2002;71:115-21 (Commentary)

Bosentan
In vivo and in vitro studies exploring the pharmacokinetic interaction between bosentan, a dual endothelin receptor antagonist, and glyburide (van Giersbergen et al). 2002;71:253-62

Busulfan
Genetic polymorphisms of glutathione S-transferase A1, the major glutathione S-transferase in human liver: consequences for enzyme expression and busulfan conjugation (Bredschneider et al). 2002;71:479-87

C

Caffeine
Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabo-

*January, pp. 1-114; February, pp. P1-P136; March, pp. 115-210; April, pp. 211-308; May, pp. 309-410; June, pp. 411-524. Index to the ASCPT meeting abstracts is located in the February issue.

lism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19) (Christensen et al). 2002;71:141-52
Pharmacology of ephedra alkaloids and caffeine after single-dose dietary supplement use (Haller et al). 2002;71:421-32

Candesartan
Comparative angiotensin II receptor blockade in healthy volunteers: the importance of dosing. 2002;71:68-76

Captopril
Renal and vascular effects of S21402, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase, in healthy subjects with hypovolemia (Chodjania et al). 2002;71:468-78

Cardiomyopathy
Angiotensin-converting enzyme inhibitor-induced syndrome of inappropriate secretion of antidiuretic hormone: case report and review of the literature (Izzedine et al). 2002;71:503-7

Cardiomyopathy, congestive
Possible mechanism for pharmacokinetic interactions between lidocaine and mexiletine (Maeda et al). 2002;71:389-97

Cariporide
Lessons learned from a phase III population pharmacokinetic study of cariporide in coronary artery bypass graft surgery (Weber et al). 2002;71:457-67

Caucasians; see Ethnic groups

CD4 lymphocyte count
CD4 response is correlated with peak plasma concentrations of indinavir in adults with undetectable human immunodeficiency virus ribonucleic acid (Anderson et al). 2002;71:280-5

CDP-771; see Gemtuzumab ozogamicin

Celecoxib

Centers for Education and Research on Therapeutics
Centers for Education and Research on Therapeutics report: survey of medication errors education during undergraduate and graduate medical education in the United States (Rosebraugh et al). 2002;71:4-10 (Commentary)

Charcoal
Combining activated charcoal with whole-bowel irrigation (Juurlink). 2002;71:404 (Letter)
Reply (Lapatto-Reiniluoto et al). 2002;71:404-5 (Letter)

Children
Extended-interval dosing of tobramycin in neonates: implications for therapeutic drug monitoring (de Hoog et al). 2002;71:349-58
Pharmacokinetic-pharmacodynamic study of oral lansoprazole in children (Tran et al). 2002;71:359-67
Pharmacokinetics and pharmacodynamics of saquinavir in pediatric patients with human immunodeficiency virus infection (Grub et al). 2002;71:122-30

Cilostazol
Pharmacokinetic and pharmacodynamic modeling of the antiplatelet and cardiovascular effects of cilostazol in healthy humans (Woo et al). 2002;71:246-52

Citrus
Effects of grapefruit juice on the pharmacokinetics of sildenafil (Jetter et al). 2002;71:21-9
Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral bioavailability of fexofenadine (Dresser et al). 2002;71:11-20

Clinical pharmacology
Angiotensin-converting enzyme inhibitor-induced syndrome of inappropriate secretion of antidiuretic hormone: case report and review of the literature (Izzedine et al). 2002;71:503-7
Possible mechanism for pharmacokinetic interactions between lidocaine and mexiletine (Maeda et al). 2002;71:389-97
Sildenafil for primary and secondary pulmonary hypertension (Watanabe et al). 2002;71:398-402

Clinical trials
Demonstration of dose response of flurbiprofen lozenges with the sore throat pain model (Schachtel et al). 2002;71:375-80
Diadenosine pentaphosphate vasodilates the forearm vascular bed: inhibition by theophylline and augmentation by dipyridamole (van Ginneken et al). 2002;71:448-56
Effects of epinephrine compared with the combination of dobutamine and norepinephrine on gastric perfusion in septic shock (Séguin et al). 2002;71:381-8
Lessons learned from a phase III population pharmacokinetic study of cariporide in coronary artery bypass graft surgery (Weber et al). 2002;71:457-67
Renal and vascular effects of S21402, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase, in healthy subjects with hypovolemia (Chodjania et al). 2002;71:468-78

Clopidogrel
Clopidogrel, but not abciximab, reduces platelet leukocyte conjugates and P-selectin expression in a human ex vivo in vitro model (Klinkhardt et al). 2002;71:176-85

CMA-676; see Gemtuzumab ozogamicin

Commentaries
Are herbal products dietary supplements or drugs? An important question for public safety (Stein). 2002;71:411-3
Centers for Education and Research on Therapeutics report: survey of medication errors education during undergraduate and graduate medical education in the United States (Rosebraugh et al). 2002;71:4-10
Changes in plasma protein binding have little clinical relevance (Benet and Hoener). 2002;71:115-21
Prioritization of medical problems to improve adherence (Paul). 2002;71:211-3
Thoughts from the Editor (Reidenberg). 2002;71:1-2
Who should have access to the research data? (Reidenberg and Reidenberg). 2002;71:309-10

Coronary artery bypass
Lessons learned from a phase III population pharmacokinetic study of cariporide in coronary artery bypass graft surgery (Weber et al). 2002;71:457-67

Correspondence; see Letters to the Editor

Coumarins
Overanticoagulation associated with combined use of antifungal agents and coumarin anticoagulants (Visser et al). 2002;71:496-502

CPC-111; see Fosfructose trisodium

Cyclosporine
Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients (Romero et al). 2002;71:226-34

Cytochrome P-450
Acute hypoxia and cytochrome P450-mediated hepatic drug metabolism in humans (Jürgens et al). 2002;71:214-20
The African-specific CYP2D6*17 allele encodes an enzyme with changed substrate specificity (Wennerholm et al). 2002;71:77-88
CYP3A4 alleles in white individuals with low CYP3A4 activity (García-Martín et al). 2002;71:196-204
Effect of growth hormone on hepatic cytochrome P450 activity in healthy elderly men (Jürgens et al). 2002;71:162-8
Effect of interferon α-ribavirin bitherapy on cytochrome P450 1A2 and 2D6 and N-acetyltransferase-2 activities in patients with chronic active hepatitis C (Becquemont et al). 2002;71:488-95
Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers (Kirchheiner et al). 2002;71:286-96
In vivo and in vitro studies exploring the pharmacokinetic interaction between bosentan, a dual endothelin receptor antagonist, and glyburide (van Giersbergen et al). 2002;71:253-62
Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19) (Christensen et al). 2002;71:141-52
Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype (Yasar et al). 2002;71:89-98
Shed human enterocytes as a tool for the study of expression and function of intestinal drug-metabolizing enzymes and transporters (Glaeser et al). 2002;71:131-40

D

Databases
Absorption, distribution, metabolism, and excretion-associated protein database (Sun et al). 2002;71:405 (Letter)
Use of a spontaneous adverse drug events database for identification of unanticipated drug benefits (Brinker and Beitz). 2002;71:99-102
Decongestant agents
Levmetamfetamine (USAN List No. 449). 2002;71:508
Diadenosine phosphate
Diadenosine pentaphosphate vasodilates the forearm vascular bed: inhibition by theophylline and augmentation by dipyridamole (van Ginneken et al). 2002;71:448-56
Dipyridamole
Diadenosine pentaphosphate vasodilates the forearm vascular bed: inhibition by theophylline and augmentation by dipyridamole (van Ginneken et al). 2002;71:448-56
Dobutamine
Effects of epinephrine compared with the combination of dobutamine and norepinephrine on gastric perfusion in septic shock (Seguin et al). 2002;71:381-8
Drug administration routes
Time course of 8-methoxypsoralen concentrations in skin and plasma after topical (bath and cream) and oral administration of 8-methoxypsoralen (Tegeder et al). 2002;71:153-61
Drug development
A modern pharmaceutical company (Erle). 2002;71:103 (Letter)
Reply (Hassan). 2002;71:103-4 (Letter)
Drug dosing
Comparative angiotensin II receptor blockade in healthy volunteers: the importance of dosing. 2002;71:68-76
Drug interactions; see also Pharmacokinetics
Are herbal products dietary supplements or drugs? An important question for public safety (Stein). 2002;71:411-3 (Commentary)
Diadenosine pentaphosphate vasodilates the forearm vascular bed: inhibition by theophylline and augmentation by dipyridamole (van Ginneken et al). 2002;71:448-56
Effect of modafinil on the pharmacokinetics of ethinyl estradiol and triazolam in healthy volunteers (Robertson et al). 2002;71:46-56
Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients (Romero et al). 2002;71:226-34
The effects of probenecid on the disposition of risperidone and olanzapine in healthy volunteers (Markowitz et al). 2002;71:30-8
Genetic polymorphisms of glutathione S-transferase A1, the major glutathione S-transferase in human liver: consequences for enzyme expression and busulfan conjugation (Bredschneider et al). 2002;71:479-87
In vivo and in vitro studies exploring the pharmacokinetic interaction between bosentan, a dual endothelin receptor antagonist, and glyburide (van Giersbergen et al). 2002;71:253-62
The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers (Aarnoutse et al). 2002;71:57-67
Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19) (Christensen et al). 2002;71:141-52
Nefazodone/nefazodone interaction (Barbey). 2002;71:403 (Letter)
Overanticoagulation associated with combined use of antifungal agents and coumarin anticoagulants (Visser et al). 2002;71:496-502
Pharmacology of ephedra alkaloids and caffeine after single-dose dietary supplement use (Haller et al). 2002;71:421-32
Possible mechanism for pharmacokinetic interactions between lidocaine and mexiletine (Maeda et al). 2002;71:389-97
Reply. (Abernethy). 2002;71:403 (Letter)
Drug monitoring
Extended-interval dosing of tobramycin in neonates: implications for therapeutic drug monitoring (de Hoog et al). 2002;71:349-58

E

Editorials; see Commentaries
Education, medical
Centers for Education and Research on Therapeutics report: survey of medication errors education during undergraduate and graduate medical education in the United States (Rosebraugh et al). 2002;71:4-10 (Commentary)
Efavirenz
The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers (Aarnoutse et al). 2002;71:57-67
Elderly; see Aged
Enalapril
Angiotensin-converting enzyme inhibitor-induced syndrome of inappropriate secretion of antidiuretic hormone: case report and review of the literature (Izzedine et al). 2002;71:503-7
Endotoxemia
Acenocoumarol decreases tissue factor-dependent coagulation during systemic inflammation in humans (Hollenstein et al). 2002;71:368-74
Energy metabolism
Acute effect of L-796568, a novel β3-adrenergic receptor agonist, on energy expenditure in obese men (van Baak et al). 2002;71:272-9
Enterocytes
Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects (Nakamura et al). 2002;71:297-303
Shed human enterocytes as a tool for the study of expression and function of intestinal drug-metabolizing enzymes and transporters (Glaeser et al). 2002;71:131-40
Ephedra
Are herbal products dietary supplements or drugs? An important question for public safety (Stein). 2002;71:411-3 (Commentary)
Pharmacology of ephedra alkaloids and caffeine after single-dose dietary supplement use (Haller et al). 2002;71:421-32
Ephedrine
Levmetamfetamine (USAN List No. 449). 2002;71:308
Epinephrine
Effects of epinephrine compared with the combination of dobutamine and norepinephrine on gastric perfusion in septic shock (Seguin et al). 2002;71:381-8
Estrogens
Stimulatory effect of cigarette smoking in the 15α-hydroxylation of estradiol by human term placenta (Zhu et al). 2002;71:311-24
Ethinyl estradiol
Effect of modafinil on the pharmacokinetics of ethinyl estradiol and triazolam in healthy volunteers (Robertson et al). 2002;71:46-56
Ethnic groups
The African-specific CYP2D6*17 allele encodes an enzyme with changed substrate specificity (Wennerholm et al). 2002;71:77-88
CYP3A4 alleles in white individuals with low CYP3A4 activity (García-Martín et al). 2002;71:196-204
Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects (Nakamura et al). 2002;71:297-303

F

Fexofenadine
Effect of St. John's wort on the pharmacokinetics of fexofenadine (Wang et al). 2002;71:414-20
Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral bioavailability of fexofenadine (Dresser et al). 2002;71:11-20
Flurbiprofen
Demonstration of dose response of flurbiprofen lozenges with the sore throat pain model (Schachtel et al). 2002;71:375-80
Fluvoxamine

Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19) (Christensen et al). 2002;71:141-52

Fosfructose trisodium

Fosfructose trisodium (USAN List No. 448). 2002;71:410

G

Gastric acid secretion

Omeprazole magnesium (USAN List No. 445). 2002;71:106

Gastrointestinal tract

Shed human enterocytes as a tool for the study of expression and function of intestinal drug-metabolizing enzymes and transporters (Glaeser et al). 2002;71:131-40

Gemtuzumab ozogamicin

Gemtuzumab ozogamicin (USAN List No. 49). 2002;71:508

Gender

Bivalirudin pharmacokinetics and pharmacodynamics: effect of renal function, dose and gender (Robson et al). 2002;71:433-9

Genes, MDR

Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects (Nakamura et al). 2002;71:297-303

Glibenclamide; see Glyburide

Globalization of industry

A modern pharmaceutical company (Erle). 2002;71:103 (Letter)

Reply (Hassan). 2002;71:103-4 (Letter)

Thoughts from the Editor (Reidenberg). 2002;71:1-2 (Commentary)

Glutathione transferase

Genetic polymorphisms of glutathione S-transferase A1, the major glutathione S-transferase in human liver: consequences for enzyme expression and busulfan conjugation (Bredschneider et al). 2002;71:479-87

Glyburide

Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers (Kirchheiner et al). 2002;71:286-96

In vivo and in vitro studies exploring the pharmacokinetic interaction between bosentan, a dual endothelin receptor antagonist, and glyburide (van Giersbergen et al). 2002;71:253-62

Gonadotropin inhibitors

Prazarelix acetate (USAN List No. 446). 2002;71:205

Grand Rounds; see Clinical pharmacology

H

Half-life

The value of plasma acetaminophen half-life in antidote-treated acetaminophen overdosage (Schiødt et al). 2002;71:221-5

Harpagophytum

Harpagophytum extracts (Chrubasik et al). 2002;71:104 (Letter)

Reply (Kaszkin). 2002;71:104-5 (Letter)

Harpagoside

Harpagophytum extracts (Chrubasik et al). 2002;71:104 (Letter)

Reply (Kaszkin). 2002;71:104-5 (Letter)

Heart disease

Fosfructose trisodium (USAN List No. 448). 2002;71:410

Heart failure

In vivo and in vitro studies exploring the pharmacokinetic interaction between bosentan, a dual endothelin receptor antagonist, and glyburide (van Giersbergen et al). 2002;71:253-62

Hepatitis

Effect of interferon α-ribavirin bitherapy on cytochrome P450 1A2 and 2D6 and N-acetyltransferase-2 activities in patients with chronic active hepatitis C (Becquemont et al). 2002;71:488-95

HIV

CD4 response is correlated with peak plasma concentrations of indinavir in adults with undetectable human immunodeficiency virus ribonucleic acid (Anderson et al). 2002;71:280-5

Pharmacokinetics and pharmacodynamics of saquinavir in pediatric patients with human immunodeficiency virus infection (Grub et al). 2002;71:122-30

Hypericum perforatum (St. John's wort)

Effect of St. John's wort on the pharmacokinetics of fexofenadine (Wang et al). 2002;71:414-20

Hypertension

Cardiovascular effect of almotriptan in treated hypertensive patients (Fleishaker et al). 2002;71:169-75

Sildenafil for primary and secondary pulmonary hypertension (Watanabe et al). 2002;71:398-402

Hyperuricemia

Rasburicase (USAN List No. 447). 2002;71:308

Hyponatremia

Angiotensin-converting enzyme inhibitor-induced syndrome of inappropriate secretion of antidiuretic hormone: case report and review of the literature (Izzedine et al). 2002;71:503-7

Hypovolemia

Renal and vascular effects of S21402, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase, in healthy subjects with hypovolemia (Chodjania et al). 2002;71:468-78

Hypoxia; see Anoxia

I

Ibuprofen

Imipenem

Tissue distribution of imipenem in critically ill patients (Tegeder et al). 2002;71:325-33

Indinavir

CD4 response is correlated with peak plasma concentrations of indinavir in adults with undetectable human immunodeficiency virus ribonucleic acid (Anderson et al). 2002;71:280-5

The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers (Aarnoutse et al). 2002;71:57-67

Infants, newborn

Extended-interval dosing of tobramycin in neonates: implications for therapeutic drug monitoring (de Hoog et al). 2002;71:349-58

Inflammation

Acenocoumarol decreases tissue factor-dependent coagulation during systemic inflammation in humans (Hollenstein et al). 2002;71:368-74

Insulin

Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers (Kirchheiner et al). 2002;71:286-96

Interferons

Effect of interferon α-ribavirin bitherapy on cytochrome P450 1A2 and 2D6 and N-acetyltransferase-2 activities in patients with chronic active hepatitis C (Becquemont et al). 2002;71:488-95

Irbesartan

Comparative angiotensin II receptor blockade in healthy volunteers: the importance of dosing. 2002;71:68-76

Irinotecan

Cholinergic toxic syndrome by the anticancer drug irinotecan: acetylcholinesterase does not play a major role (Blandizzi et al). 2002;71:263-71

Irrigation

Combining activated charcoal with whole-bowel irrigation (Juurlink). 2002;71:404 (Letter)

Reply (Lapatto-Reiniluoto et al). 2002;71:404-5 (Letter)

K

Keppra(tm); see Levetiracetam

Kidney failure

Bivalirudin pharmacokinetics and pharmacodynamics: effect of renal function, dose and gender (Robson et al). 2002;71:433-9

Tissue distribution of imipenem in critically ill patients (Tegeder et al). 2002;71:325-33

Kidney transplantation

Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients (Romero et al). 2002;71:226-34

L

l-Desoxyephedrine; see Levmetamfetamine
L-796568
Acute effect of L-796568, a novel β3-adrenergic receptor agonist, on energy expenditure in obese men (van Baak et al). 2002;71:272-9
Lansoprazole
Pharmacokinetic-pharmacodynamic study of oral lansoprazole in children (Tran et al). 2002;71:359-67
Lesch-Nyhan syndrome
Rasburicase (USAN List No. 447). 2002:71:308
Letters to the Editor
Combining activated charcoal with whole-bowel irrigation (Juurlink). 2002;71:404
Determination of maximum effect (Sheiner and Holford). 2002;71:304
Harpagophytum extracts (Chrubasik et al). 2002;71:104
Loratadine/nefazodone interaction (Barbey). 2002;71:403
A modern pharmaceutical company (Erle). 2002;71:103
Reply. (Abernethy). 2002;71:403
Reply (du Souich and Vergés). 2002;71:304-5
Reply (Hassan). 2002;71:103-4
Reply (Kaszkin). 2002;71:104-5
Reply (Lapatto-Reiniluoto et al). 2002;71:404-5
Levetiracetam
Levetiracetam (USAN List No. 445). 2002:71:106
Levmetamfetamine
Levmetamfetamine (USAN List No. 449). 2002:71:508
Lidocaine
Possible mechanism for pharmacokinetic interactions between lidocaine and mexiletine (Maeda et al). 2002;71:389-97
Loratadine
Nefazodone/nefazodone interaction (Barbey). 2002;71:403 (Letter)
Reply. (Abernethy). 2002;71:403 (Letter)
Losartan
Comparative angiotensin II receptor blockade in healthy volunteers: the importance of dosing. 2002;71:68-76
Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype (Yasar et al). 2002;71:89-98

M

Ma huang
Pharmacology of ephedra alkaloids and caffeine after single-dose dietary supplement use (Haller et al). 2002;71:421-32
Medication errors
Centers for Education and Research on Therapeutics report: survey of medication errors education during undergraduate and graduate medical education in the United States (Rosebraugh et al). 2002;71:4-10 (Commentary)
Medicine, herbal
Are herbal products dietary supplements or drugs? An important question for public safety (Stein). 2002;71:411-3 (Commentary)
Effect of St. John's wort on the pharmacokinetics of fexofenadine (Wang et al). 2002;71:414-20
Harpagophytum extracts (Chrubasik et al). 2002;71:104 (Letter)
Pharmacology of ephedra alkaloids and caffeine after single-dose dietary supplement use (Haller et al). 2002;71:421-32
Reply (Kaszkin). 2002;71:104-5 (Letter)
Megakaryocyte stimulatory factor
Pegacaristim (USAN List No. 448). 2002:71:410
Metabolism
Acute hypoxia and cytochrome P450-mediated hepatic drug metabolism in humans (Jürgens et al). 2002;71:214-20
Effects of grapefruit juice on the pharmacokinetics of sildenafil (Jetter et al). 2002;71:21-9
Methoxsalen
Time course of 8-methoxypsoralen concentrations in skin and plasma after topical (bath and cream) and oral administration of 8-methoxypsoralen (Tegeder et al). 2002;71:153-61
Mexiletine
Possible mechanism for pharmacokinetic interactions between lidocaine and mexiletine (Maeda et al). 2002;71:389-97
Miconazole
Overanticoagulation associated with combined use of antifungal agents and coumarin anticoagulants (Visser et al). 2002;71:496-502
Modafinil
Effect of modafinil on the pharmacokinetics of ethinyl estradiol and triazolam in healthy volunteers (Robertson et al). 2002;71:46-56
Myocardial ischemia
Fosfructose trisodium (USAN List No. 448). 2002:71:410

N

Nefazodone
Nefazodone/nefazodone interaction (Barbey). 2002;71:403 (Letter)
Reply. (Abernethy). 2002;71:403 (Letter)
Nitroglycerin
Angiotensin II attenuates the vasodilating effect of a nitric oxide donor, glyceryl trinitrate: roles of superoxide and angiotensin II type 1 receptors. 2002;71:440-7
Norepinephrine
Effects of epinephrine compared with the combination of dobutamine and norepinephrine on gastric perfusion in septic shock (Seguin et al). 2002;71:381-8

O

Obesity
Acute effect of L-796568, a novel β3-adrenergic receptor agonist, on energy expenditure in obese men (van Baak et al). 2002;71:272-9
Olanzapine
The effects of probenecid on the disposition of risperidone and olanzapine in healthy volunteers (Markowitz et al). 2002;71:30-8
Omeprazole
Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19) (Christensen et al). 2002;71:141-52
Omeprazole magnesium
Omeprazole magnesium (USAN List No. 445). 2002:71:106
Onconase®; see Ranpirnase
Organic anion transporters
Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral bioavailability of fexofenadine (Dresser et al). 2002;71:11-20
Overdose
Combining activated charcoal with whole-bowel irrigation (Juurlink). 2002;71:404 (Letter)
Reply (Lapatto-Reiniluoto et al). 2002;71:404-5 (Letter)
The value of plasma acetaminophen half-life in antidote-treated acetaminophen overdosage (Schiødt et al). 2002;71:221-5

P

P30 protein; see Ranpirnase
Pain
Demonstration of dose response of flurbiprofen lozenges with the sore throat pain model (Schachtel et al). 2002;71:375-80
Paracetamol; see Acetaminophen
Patient adherence
Prioritization of medical problems to improve adherence (Paul). 2002:71:211-3 (Commentary)
Pegacaristim
Pegacaristim (USAN List No. 448). 2002:71:410
P-glycoprotein
Pharmacodynamics
Absorption, distribution, metabolism, and excretion-associated protein database (Sun et al). 2002;71:405 (Letter)
Acenocoumarol decreases tissue factor-dependent coagulation during systemic inflammation in humans (Hollenstein et al). 2002;71:368-74

Angiotensin II attenuates the vasodilating effect of a nitric oxide donor, glyceryl trinitrate: roles of superoxide and angiotensin II type 1 receptors. 2002;71:440-7
Bivalirudin pharmacokinetics and pharmacodynamics: effect of renal function, dose and gender (Robson et al). 2002;71:433-9
Cardiovascular effect of almotriptan in treated hypertensive patients (Fleishaker et al). 2002;71:169-75
CD4 response is correlated with peak plasma concentrations of indinavir in adults with undetectable human immunodeficiency virus ribonucleic acid (Anderson et al). 2002;71:280-5
Cholinergic toxic syndrome by the anticancer drug irinotecan: acetylcholinesterase does not play a major role (Blandizzi et al). 2002;71:263-71
Clopidogrel, but not abciximab, reduces platelet leukocyte conjugates and P-selectin expression in a human ex vivo in vitro model (Klinkhardt et al). 2002;71:176-85
Comparative angiotensin II receptor blockade in healthy volunteers: the importance of dosing. 2002;71:68-76
Determination of maximum effect (Sheiner and Holford). 2002;71:304 (Letter)
Effect of growth hormone on hepatic cytochrome P450 activity in healthy elderly men (Jürgens et al). 2002;71:162-8
Pharmacodynamics of abciximab during angioplasty: comparison to healthy subjects (Abernethy et al). 2002;71:186-95
Pharmacokinetic and pharmacodynamic modeling of the antiplatelet and cardiovascular effects of cilostazol in healthy humans (Woo et al). 2002;71:246-52
Pharmacokinetic-pharmacodynamic study of oral lansoprazole in children (Tran et al). 2002;71:359-67
Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors (Mould et al). 2002;71:334-48
Reply (du Souich and Vergés). 2002;71:304-5 (Letter)

Pharmacoepidemiology

Overanticoagulation associated with combined use of antifungal agents and coumarin anticoagulants (Visser et al). 2002;71:496-502
Use of a spontaneous adverse drug events database for identification of unanticipated drug benefits (Brinker and Beitz). 2002;71:99-102

Pharmacogenetics

The African-specific CYP2D6*17 allele encodes an enzyme with changed substrate specificity (Wennerholm et al). 2002;71:77-88
CYP3A4 alleles in white individuals with low CYP3A4 activity (García-Martín et al). 2002;71:196-204
Effect of interferon α-ribavirin bitherapy on cytochrome P450 1A2 and 2D6 and N-acetyltransferase-2 activities in patients with chronic active hepatitis C (Becquemont et al). 2002;71:488-95
Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects (Nakamura et al). 2002;71:297-303
Genetic polymorphisms of glutathione S-transferase A1, the major glutathione S-transferase in human liver: consequences for enzyme expression and busulfan conjugation (Bredschneider et al). 2002;71:479-87
Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers (Kirchheiner et al). 2002;71:286-96
Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype (Yasar et al). 2002;71:89-98

Pharmacokinetics; see also Drug interactions

Absorption, distribution, metabolism, and excretion-associated protein database (Sun et al). 2002;71:405 (Letter)
Acute hypoxia and cytochrome P450-mediated hepatic drug metabolism in humans (Jürgens et al). 2002;71:214-20
Bivalirudin pharmacokinetics and pharmacodynamics: effect of renal function, dose and gender (Robson et al). 2002;71:433-9
Changes in plasma protein binding have little clinical relevance (Benet and Hoener). 2002;71:115-21 (Commentary)
Determination of maximum effect (Sheiner and Holford). 2002;71:304 (Letter)
Effect of St. John's wort on the pharmacokinetics of fexofenadine (Wang et al). 2002;71:414-20
Effects of grapefruit juice on the pharmacokinetics of sildenafil (Jetter et al). 2002;71:21-9
Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral bioavailability of fexofenadine (Dresser et al). 2002;71:11-20
Pharmacodynamics of abciximab during angioplasty: comparison to healthy subjects (Abernethy et al). 2002;71:186-95
Pharmacokinetic and pharmacodynamic modeling of humanized anti-factor IX antibody (SB 249417) in humans (Chow et al). 2002;71:235-45
Pharmacokinetic and pharmacodynamic modeling of the antiplatelet and cardiovascular effects of cilostazol in healthy humans (Woo et al). 2002;71:246-52
Pharmacokinetic-pharmacodynamic study of oral lansoprazole in children (Tran et al). 2002;71:359-67
Pharmacokinetics and pharmacodynamics of saquinavir in pediatric patients with human immunodeficiency virus infection (Grub et al). 2002;71:122-30
Pharmacokinetics of betamethasone in twin and singleton pregnancy (Ballabh et al). 2002;71:39-45
Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype (Yasar et al). 2002;71:89-98
Pharmacology of ephedra alkaloids and caffeine after single-dose dietary supplement use (Haller et al). 2002;71:421-32
Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors (Mould et al). 2002;71:334-48
Possible mechanism for pharmacokinetic interactions between lidocaine and mexiletine (Maeda et al). 2002;71:389-97
Reply (du Souich and Vergés). 2002;71:304-5 (Letter)
Shed human enterocytes as a tool for the study of expression and function of intestinal drug-metabolizing enzymes and transporters (Glaeser et al). 2002;71:131-40
Stimulatory effect of cigarette smoking in the 15α-hydroxylation of estradiol by human term placenta (Zhu et al). 2002;71:311-24
Time course of 8-methoxypsoralen concentrations in skin and plasma after topical (bath and cream) and oral administration of 8-methoxypsoralen (Tegeder et al). 2002;71:153-61
Tissue distribution of imipenem in critically ill patients (Tegeder et al). 2002;71:325-33
The value of plasma acetaminophen half-life in antidote-treated acetaminophen overdosage (Schiødt et al). 2002;71:221-5

Placenta

Stimulatory effect of cigarette smoking in the 15α-hydroxylation of estradiol by human term placenta (Zhu et al). 2002;71:311-24

Platelet aggregation inhibitors

Clopidogrel, but not abciximab, reduces platelet leukocyte conjugates and P-selectin expression in a human ex vivo in vitro model (Klinkhardt et al). 2002;71:176-85
Pharmacokinetic and pharmacodynamic modeling of the antiplatelet and cardiovascular effects of cilostazol in healthy humans (Woo et al). 2002;71:246-52

Polymorphism (genetics)

Genetic polymorphisms of glutathione S-transferase A1, the major glutathione S-transferase in human liver: consequences for enzyme expression and busulfan conjugation (Bredschneider et al). 2002;71:479-87
Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers (Kirchheiner et al). 2002;71:286-96

Population studies

Lessons learned from a phase III population pharmacokinetic study of cariporide in coronary artery bypass graft surgery (Weber et al). 2002;71:457-67
Overanticoagulation associated with combined use of antifungal agents and coumarin anticoagulants (Visser et al). 2002;71:496-502
Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors (Mould et al). 2002;71:334-48

Prazarelix acetate
Prazarelix acetate (USAN List No. 446). 2002;71:205
Pregnancy
Pharmacokinetics of betamethasone in twin and singleton pregnancy (Ballabh et al). 2002;71:39-45
Probenecid
The effects of probenecid on the disposition of risperidone and olanzapine in healthy volunteers (Markowitz et al). 2002;71:30-8
Protein binding
Changes in plasma protein binding have little clinical relevance (Benet and Hoener). 2002;71:115-21 (Commentary)
Proteins
Absorption, distribution, metabolism, and excretion-associated protein database (Sun et al). 2002;71:405 (Letter)
P-selectin
Clopidogrel, but not abciximab, reduces platelet leukocyte conjugates and P-selectin expression in a human ex vivo in vitro model (Klinkhardt et al). 2002;71:176-85
PUVA therapy
Time course of 8-methoxypsoralen concentrations in skin and plasma after topical (bath and cream) and oral administration of 8-methoxypsoralen (Tegeder et al). 2002;71:153-61

R

Ranpirnase
Ranpirnase (USAN List No. 446). 2002:71:205
Rasburicase
Rasburicase (USAN List No. 447). 2002:71:308
Receptors, angiotensin
Comparative angiotensin II receptor blockade in healthy volunteers: the importance of dosing. 2002;71:68-76
Research
Thoughts from the Editor (Reidenberg). 2002;71:1-2 (Commentary)
Who should have access to the research data? (Reidenberg and Reidenberg). 2002;71:309-10 (Commentary)
Ribavirin
Effect of interferon α-ribavirin bitherapy on cytochrome P450 1A2 and 2D6 and N-acetyltransferase-2 activities in patients with chronic active hepatitis C (Becquemont et al). 2002;71:488-95
Risperidone
The effects of probenecid on the disposition of risperidone and olanzapine in healthy volunteers (Markowitz et al). 2002;71:30-8
Ritonavir
The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers (Aarnoutse et al). 2002;71:57-67
RWJ 47428; see Prazarelix acetate

S

S21402
Renal and vascular effects of S21402, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase, in healthy subjects with hypovolemia (Chodjania et al). 2002;71:468-78
Saquinavir
Pharmacokinetics and pharmacodynamics of saquinavir in pediatric patients with human immunodeficiency virus infection (Grub et al). 2002;71:122-30
SB 249417
Pharmacokinetic and pharmacodynamic modeling of humanized anti-factor IX antibody (SB 249417) in humans (Chow et al). 2002;71:235-45
Selamectin
Selamectin (USAN List No. 447). 2002:71;307
Shock, septic
Effects of epinephrine compared with the combination of dobutamine and norepinephrine on gastric perfusion in septic shock (Seguin et al). 2002;71:381-8
Sildenafil
Effects of grapefruit juice on the pharmacokinetics of sildenafil (Jetter et al). 2002;71:21-9
Sildenafil for primary and secondary pulmonary hypertension (Watanabe et al). 2002;71:398-402
Smoking
Stimulatory effect of cigarette smoking in the 15α-hydroxylation of estradiol by human term placenta (Zhu et al). 2002;71:311-24
Somatotropins, recombinant
Effect of growth hormone on hepatic cytochrome P450 activity in healthy elderly men (Jürgens et al). 2002;71:162-8
SR29142; see Rasburicase
St. John's wort; see Hypericum perforatum (St. John's wort)
Superoxides
Angiotensin II attenuates the vasodilating effect of a nitric oxide donor, glyceryl trinitrate: roles of superoxide and angiotensin II type 1 receptors. 2002;71:440-7

T

Theophylline
Diadenosine pentaphosphate vasodilates the forearm vascular bed: inhibition by theophylline and augmentation by dipyridamole (van Ginneken et al). 2002;71:448-56
Thrombocytopenia
Pegacaristim (USAN List No. 448). 2002:71;410
Tobramycin
Extended-interval dosing of tobramycin in neonates: implications for therapeutic drug monitoring (de Hoog et al). 2002;71:349-58
Topotecan
Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors (Mould et al). 2002;71:334-48
Triazolam
Effect of modafinil on the pharmacokinetics of ethinyl estradiol and triazolam in healthy volunteers (Robertson et al). 2002;71:46-56

U

UK-124,114; see Selamectin

V

Valsartan
Comparative angiotensin II receptor blockade in healthy volunteers: the importance of dosing. 2002;71:68-76
Vasodilation
Angiotensin II attenuates the vasodilating effect of a nitric oxide donor, glyceryl trinitrate: roles of superoxide and angiotensin II type 1 receptors. 2002;71:440-7
Diadenosine pentaphosphate vasodilates the forearm vascular bed: inhibition by theophylline and augmentation by dipyridamole (van Ginneken et al). 2002;71:448-56
Vasopressins
Angiotensin-converting enzyme inhibitor-induced syndrome of inappropriate secretion of antidiuretic hormone: case report and review of the literature (Izzedine et al). 2002;71:503-7
Voriconazole
Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients (Romero et al). 2002;71:226-34

W

WAY-CMA-676; see Gemtuzumab ozogamicin